MedTrace Logo

Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer

NCT03374995 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-06-11

Study results available
· View outcomes & findings →

Summary

This randomized pilot clinical trial studies how well topical keratin works in treating radiation dermatitis in patients with breast cancer. Radiation dermatitis is a skin condition that is a common side effect of radiation therapy. The affected skin becomes painful, red, itchy, and blistered. Topical keratin may help to improve skin appearance and hydration in patients with breast cancer.

Conditions

  • Breast Carcinoma
  • Radiation-Induced Dermatitis

Interventions

OTHER

Best Practice

Receive standard of care

OTHER

Quality-of-Life Assessment

Ancillary studies

DEVICE

Topical Keratin

Given topically

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Karen Winkfield · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-26
Primary Completion
2018-11-01
Completion
2018-11-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03374995 on ClinicalTrials.gov